Alnylam Pharmaceuticals (ALNY) Interest Expenses (2020 - 2026)

Alnylam Pharmaceuticals (ALNY) has 14 years of Interest Expenses data on file, last reported at $82.1 million in Q2 2026.

• Quarterly Interest Expenses rose 33.51% year-over-year to $82.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $195.8 million (down 3.88% YoY) and the FY2025 annual result came in at $252.6 million, down 90.94% from the prior year.
• Interest Expenses climbed to $82.1 million in Q2 2026, from $69.3 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $82.1 million in Q2 2026 to a low of $100000.0 in Q4 2025.
• A 5-year average of $41.4 million and a median of $37.1 million in 2024 frame the typical range for Interest Expenses.
• The widest YoY moves for Interest Expenses: up 95.53% in 2025, down 99.74% in 2025.
• Tracing ALNY's Interest Expenses over 5 years: stood at $29.9 million in 2022, then grew by 4.76% to $31.3 million in 2023, then advanced by 24.36% to $39.0 million in 2024, then slumped by 99.74% to $100000.0 in 2025, then soared by 81951.0% to $82.1 million in 2026.
• The last three Interest Expenses figures came in at $82.1 million (Q2 2026), $69.3 million (Q1 2026), and $100000.0 (Q4 2025), per Business Quant data.